Blood test may predict who wins lung cancer fight
NCT ID NCT07363811
Summary
This study aims to find out if measuring a specific type of white blood cell, called large granular lymphocytes (LGLs), can help predict how well patients with advanced non-small cell lung cancer will respond to the immunotherapy drug nivolumab. Researchers will enroll 50 patients and track their LGL levels at the start of treatment and after three months, comparing these levels to how their cancer responds and how long they survive. The goal is to gather knowledge that could one day help doctors better personalize treatment plans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Necmettin Erbakan University Faculty of Medicine, Department of Medical Oncology
RECRUITINGKonya, Meram, 42090, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.